Daniel Herr

Daniel Herr

Auto-generated profile, based on publicly available information

Daniel Herr

Department of Obstetrics and GynecologyUniversity of Würzburg, Josef-Schneider-Str. 4, 97080 Würzburg, GermanyDepartment of Obstetrics and GynecologyUlm University Medical Centre, Ulm, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
DHDaniel Herr
Daniel Herr
IBInga Bekes
Inga Bekes
CWChristine Wulff
Christine Wulff
The renin–angiotensin system (RAS) is well known as regulator of electrolytes and blood pressure. Besides this function, there are numerous studies supporting the idea of a local tissue RAS. This system controls the local activity of the different RAS family members, especially of the functional proteins Angiotensin II and Angiotensin (1-7). Those antagonistically acting proteins have been described to be expressed in different organ systems including the human reproductive tract. Therefore, this local RAS has been suspected to be involved in the control and regulation of physiological and pathological conditions in the female reproduction tract. This review of the available literature summarizes the physiological influence of the RAS on the follicular development, ovarian angiogenesis and placental- and uterine function. In addition, in the second part the role of the RAS concerning ovarian- and endometrial cancer becomes elucidated. This section includes possible novel therapeutic strategies via inhibition of RAS-mediated tumor growth and angiogenesis. Looking at a very complex system of agonistic and antagonistic tissue factors, it may be supposed that the RAS in the female reproduction tract will be of rising scientific interest in the upcoming years.

1 January 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DHDaniel Herr
Daniel Herr
JKJochem König
Jochem König
VHVolker Heilmann
Volker Heilmann
KKKarin Koretz
Karin Koretz
RKRolf Kreienberg
Rolf Kreienberg
CKChristian Kurzeder
Christian Kurzeder

4 April 2006 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
BPB. Phan
B. Phan
ARA. Rakenius
A. Rakenius
DPD. Pietrowski
D. Pietrowski
HBH. Bettendorf
H. Bettendorf
CKC. Keck
C. Keck
DHD. Herr
D. Herr

1 February 2015 in Reproduction
Verified
Journal Article
Closed access
DHDaniel Herr
Daniel Herr
IBInga Bekes
Inga Bekes
CWChristine Wulff
Christine Wulff
In a developing human corpus luteum, a closely regulated cellular communication system exists between the luteal steroidogenic cells and endothelial cells. This system guaranties the vascularization process during luteal formation. The process is combined with rapid release of large amounts of progesterone into the bloodstream. The regulation of endothelial proliferation and permeability by LH and human chorionic gonadotropin (hCG) is integral to this process. On the cellular level, endothelial permeability is regulated by intercellular junctions, such as adherens junctions (AJ) and tight junctions (TJ), which act as zipper-like structures between interacting endothelial cells. Several cell junctional proteins are localized to the corpus luteum, including Occludin, Nectin 2, Claudin 1, and Claudin 5, as well as, vascular endothelial (VE)-Cadherin. It has been assumed that regulation of AJ- and TJ-proteins is of particular importance for permeability, and accordingly, for the functionality of the corpus luteum in early pregnancy, because treatment with hCG induces downregulation of juntional proteins in the luteal vessels. The effect of hCG on the adhesive molecules is mediated by VE growth factor (VEGF). On a functional level, the hCG-dependent and VEGF-mediated decrease in junctional proteins causes a decrease in the density of cell–cell closure and, accordingly, an increase in endothelial permeability. In doing so, the different junctional proteins are not only directly influenced by VEGF but also interact among themselves and influence each other reciprocally. Disturbances in this strictly, regulated interactions may explain the development of pathologies with increased vascular permeability, such as the ovarian hyperstimulation syndrome.

12 July 2006 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
DHD. Herr
D. Herr
HBH. Bettendorf
H. Bettendorf
DDD. Denschlag
D. Denschlag
CKC. Keck
C. Keck
DPD. Pietrowski
D. Pietrowski

1 March 2014 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
DHD. Herr
D. Herr
IJI. Juhasz-Boess
I. Juhasz-Boess
ESE. F. Solomayer
E. F. Solomayer
The rather rare vulvar cancer is almost always a squamous cell carcinoma that mostly develops from an underlying VIN or HPV infection. In addition, lichen sclerosus et atrophicans, immune deficiency, nicotine abuse or anogenital intraepithelial neoplasias may play a role in the pathogenesis. Surgical therapy aims at an R0 resection in the sense of a complete vulvectomy or a radical local excision with, if necessary, plastic reconstruction. Also, the vulvar field resection with consideration of the compartment model has been discussed. Besides the classic inguinofemoral lymphadenectomy, in selected cases of vulvar cancer sentinel biopsies are performed by experienced surgeons in the larger centres. In contrast, systemic therapy plays only a subordinate role; in isolated cases down-staging by means of neoadjuvant chemotherapy may be useful. However, there is at present no indication for adjuvant chemotherapy. Neoadjuvant radiochemotherapy is also not to be recommended on account of its unfavourable ratio of efficacy to side effects. On the other hand adjuvant radiotherapy is indicated in cases of positive inguinal lymph nodes. According to the current data the indication should be made generously in such cases. Das eher seltene Vulvakarzinom ist fast immer ein Plattenepithelkarzinom, das meist auf dem Boden einer vulvären intraepithelialen Neoplasie (VIN) oder einer HPV-Infektion entsteht. Daneben sind auch der Lichen sclerosus et atrophicans, eine Immundefizienz, Nikotinabusus oder anogenitale intraepitheliale Neoplasien an der Pathogenese beteiligt. Die operative Therapie zielt auf eine R0-Resektion im Sinne einer kompletten Vulvektomie oder einer radikalen lokalen Exzision ggf. mit plastischer Rekonstruktion. Daneben wird zunehmend auch die Vulvafeldresektion unter Berücksichtigung des Kompartment-Modells diskutiert. Neben der klassischen inguinofemoralen Lymphonodektomie wird auch beim Vulvakarzinom die Sentinel-Biopsie in größeren Zentren und ausgewählten Situationen von erfahrenen Operateuren durchgeführt. Die Systemtherapie spielt dagegen eine nur untergeordnete Rolle; in Einzelfällen kann ein Downstaging durch eine neoadjuvante Chemotherapie sinnvoll sein. Für eine adjuvante Chemotherapie gibt es derzeit keine Indikation. Ebenfalls sollte eine neoadjuvante Radiochemotherapie aufgrund der ungünstigen Ratio an Effektivität und Nebenwirkungen vermieden werden. Im Gegensatz dazu ist eine adjuvante Bestrahlung aber bei positiven inguinalen Lymphknoten indiziert. Hierzu sollte die Indikation nach aktuellen Daten großzügig gestellt werden.